Cytomegalovirus Viral Load Threshold to Guide Preemptive Therapy in Hematopoietic Cell Transplant Recipients: Correlation With Cytomegalovirus Disease.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE
    • Publication Information:
      Publication: Jan. 2011- : Oxford : Oxford University Press
      Original Publication: 1904-2010 : Chicago, IL : University of Chicago Press
    • Subject Terms:
      Cytomegalovirus Infections*/prevention & control ; Cytomegalovirus Infections*/virology ; Viral Load* ; Hematopoietic Stem Cell Transplantation*/adverse effects ; Cytomegalovirus*/physiology ; Antiviral Agents*/therapeutic use ; Antiviral Agents*/administration & dosage; Humans ; Transplant Recipients ; Randomized Controlled Trials as Topic ; Observational Studies as Topic
    • Abstract:
      A systematic review of randomized and observational studies from 2013 to 2023 demonstrated that antiviral preemptive therapy started at cytomegalovirus viral load thresholds between 2 and 3 log10 IU/mL was associated with similar cytomegalovirus disease rates. Thus, viral thresholds in this range appear to effectively protect patients not receiving prophylaxis.
      Competing Interests: Potential conflicts of interest. A. P. L. has received research support from Merck and Takeda; served as a consultant for GSK, Vera, AiCuris, Merck, and Moderna; and served on a data safety and monitoring board for Novartis, Syneos, and Nobelpharma. M. B. received research support from Merck and served as a consultant for Allovir, Symbio Pharmaceuticals, Moderna, and Merck. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
      (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: [email protected].)
    • References:
      J Clin Microbiol. 2019 Dec 23;58(1):. (PMID: 31619529)
      Biol Blood Marrow Transplant. 2020 Oct;26(10):1963-1970. (PMID: 32653623)
      Clin Transplant. 2020 Jul;34(7):e13866. (PMID: 32242979)
      Biol Blood Marrow Transplant. 2019 Feb;25(2):369-381. (PMID: 30292744)
      Biol Blood Marrow Transplant. 2020 Aug;26(8):1482-1491. (PMID: 32315708)
      Ann Hematol. 2021 Aug;100(8):2087-2093. (PMID: 33270162)
      Clin Infect Dis. 2002 Apr 15;34(8):1094-7. (PMID: 11914998)
      N Engl J Med. 2013 Sep 26;369(13):1227-36. (PMID: 24066743)
      Blood Adv. 2023 Apr 25;7(8):1394-1403. (PMID: 36595478)
      N Engl J Med. 2017 Dec 21;377(25):2433-2444. (PMID: 29211658)
      Lancet Haematol. 2016 Mar;3(3):e119-27. (PMID: 26947200)
      Clin Infect Dis. 2016 Sep 1;63(5):583-9. (PMID: 27307504)
      Clin Infect Dis. 2017 Jan 1;64(1):87-91. (PMID: 27682069)
    • Grant Information:
      Polish National Agency for Academic Exchange; UG3 HL147011 United States HL NHLBI NIH HHS; HHSN272201600015C United States NH NIH HHS; Meyers Scholarship Endowment; Center; UH3 HL147011 United States HL NHLBI NIH HHS; Fred Hutchinson Cancer
    • Contributed Indexing:
      Keywords: CMV; CMV disease; preemptive therapy; review; viral load threshold
    • Publication Date:
      Date Created: 20230908 Date Completed: 20240515 Latest Revision: 20240712
    • Publication Date:
      20240712
    • Accession Number:
      PMC11095528
    • Accession Number:
      10.1093/infdis/jiad386
    • Accession Number:
      37682870